• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Positive Results in Phase III Trials Using XXII's Very Low Nicotine Cigarettes

October 6, 2017

 

Bad news for competing tobacco companies like Altria Group Inc. (NYSE:MO) and Philip Morris (NYSE:PM), this morning 22nd Century Group, Inc. (NYSE:XXII), announced that Dr. Dorothy Hatsukami, at the Vermont Center on Behavior and Health’s 5th Annual Conference on Tobacco Regulatory Science, revealed positive results from a "ground-breaking phase III study that was conducted in 10 cities across the United States and included participants from all demographics."

 

The study was conducted by Dr. Hatsukami, who is the Co-Director of the Center for the Evaluation of Nicotine in Cigarettes and Professor of Psychiatry and Director of the Tobacco Research Programs at the University of Minnesota. Spanning over 20 weeks with 1,250 patients, the study compared smokers who were assigned to three categories:

  1. an immediate reduction to Very Low Nicotine cigarettes 

  2. gradual reduction in reduced nicotine content cigarettes 

  3. normal nicotine content cigarettes  

 

These incredibly exciting Phase III results were announced just weeks after the FDA announced their plans to mandate lower nicotine in cigarettes, in all combustible cigarettes sold throughout the U.S.  The implementation of VLN (very low nicotine tobacco) in cigarettes could save an insurmountable number of lives.

 

With the announcement coming out before this morning's North American market open, shares of 22nd Century soared all the way up to $3.85 pre-market on above average volume.

 

Recently, 22nd Century announced that they had been freed from their restrictive licensing agreement with British American Tobacco Plc (NYSE:BTI), now leaving them open to license their very low nicotine technology to whoever they like. Whether XXII's patent portfolio is licensed to Altria Group Inc. and Philip Morris International Inc. or whichever fat-walleted suitor can afford it, it will be worth it. 

 

Only time will tell how the market responds throughout the rest of the trading day. To get all of our 22nd Century Updates, make sure to sign up to our XXII updates list here. Be sure to subscribe to one or more of our free e-mail newsletters so you never miss an important update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, and Instagram.

 

D/M/O

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.